Page last updated: 2024-12-07

1-methylcytosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-methylcytosine (1mC) is a naturally occurring modified base found in DNA. It is formed by the methylation of cytosine at the N1 position. This methylation is catalyzed by DNA methyltransferases (DNMTs), which play a crucial role in regulating gene expression. 1mC is found in various organisms, including bacteria, plants, and animals. In mammals, 1mC is a key epigenetic mark that influences gene expression by altering chromatin structure and recruiting specific proteins to DNA. 1mC is involved in a wide range of biological processes, including development, differentiation, and disease. Aberrant methylation patterns are associated with various diseases, such as cancer. 1mC is extensively studied to understand its role in epigenetic regulation, gene expression, and disease pathogenesis. Research efforts focus on identifying the mechanisms of 1mC formation, its functional consequences, and its potential as a therapeutic target.'

1-methylcytosine: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

1-methylcytosine : A pyrimidone that is cytosine in which the hydrogen attached to the nitrogen at position 1 is substituted by a methyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID79143
CHEMBL ID500883
CHEBI ID39624
SCHEMBL ID19929
SCHEMBL ID20879444
MeSH IDM0098995

Synonyms (55)

Synonym
nsc 47693
1j54ne82rv ,
2(1h)-pyrimidinone, 4-amino-1-methyl-
unii-1j54ne82rv
nsc-47693
1122-47-0
nsc47693
4-amino-2-hydroxy-1-methylpyrimidine
2(1h)-pyrimidinone,4-amino-1-methyl-
n-methylcytosine
1BKY
DB04314
1-methylcytosine
1MC ,
1-methylcytosin
CHEMBL500883
chebi:39624 ,
FT-0693607
4-amino-1-methylpyrimidin-2-one
AKOS005266250
4-amino-1-methylpyrimidin-2(1h)-one ,
HWPZZUQOWRWFDB-UHFFFAOYSA-N
4-amino-1-methyl-1h-pyrimidin-2-one
SCHEMBL19929
4-amino-1-methyl-pyrimidin-2-one
4-amino-1-methyl-2(1h)-pyrimidinone
AC-31819
DTXSID60149949
176112-79-1
2-pyrimidinol,1,4-dihydro-4-imino-1-methyl-,(z)-
CS-W006395
mfcd00038058
methylcytosine
176112-77-9
176158-70-6
176112-78-0
Q27095132
cytosine, 1-methyl-
n1-methylcytosine
PS-11898
AMY5656
HY-W006395
SCHEMBL20879444
A894624
SB57304
CS1032
2(1h)-pyrimidinone,3,4-dihydro-4-imino-1-methyl-,(4e)-(9ci)
2-pyrimidinol,1,4-dihydro-4-imino-1-methyl-,(e)-(9ci)
2(1h)-pyrimidinone,3,4-dihydro-4-imino-1-methyl-,(z)-(9ci)
BAA12247
PD006316
4-amino-1-methyl-1,2-dihydropyrimidin-2-one
EN300-263946
SY070177
Z1198148063
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
pyrimidoneA pyrimidine carrying one or more oxo substituents.
aminopyrimidineA member of the class of pyrimidines that is pyrimidine substituted by at least one amino group and its derivatives.
methylcytosine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, VP39Vaccinia virusKd144.000085.5000114.7500144.0000AID977611
Chain A, VP39Vaccinia virusKd144.000085.5000114.7500144.0000AID977611
Chain A, VP39Vaccinia virusKd144.000085.5000114.7500144.0000AID977611
Chain A, VP39Vaccinia virusKd144.000085.5000114.7500144.0000AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID1811Experimentally measured binding affinity data derived from PDB1999Proceedings of the National Academy of Sciences of the United States of America, Jun-22, Volume: 96, Issue:13
mRNA cap recognition: dominant role of enhanced stacking interactions between methylated bases and protein aromatic side chains.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB1999Proceedings of the National Academy of Sciences of the United States of America, Jun-22, Volume: 96, Issue:13
mRNA cap recognition: dominant role of enhanced stacking interactions between methylated bases and protein aromatic side chains.
AID352124Growth inhibition of human SW620 cells after 72 hrs by MTT assay2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
Synthesis of modified pyrimidine bases and positive impact of chemically reactive substituents on their in vitro antiproliferative activity.
AID352122Growth inhibition of human HeLa cells after 72 hrs by MTT assay2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
Synthesis of modified pyrimidine bases and positive impact of chemically reactive substituents on their in vitro antiproliferative activity.
AID352126Growth inhibition of human H460 cells after 72 hrs by MTT assay2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
Synthesis of modified pyrimidine bases and positive impact of chemically reactive substituents on their in vitro antiproliferative activity.
AID352123Growth inhibition of human MIAPaCa2 cells after 72 hrs by MTT assay2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
Synthesis of modified pyrimidine bases and positive impact of chemically reactive substituents on their in vitro antiproliferative activity.
AID352125Growth inhibition of human MCF7 cells after 72 hrs by MTT assay2009European journal of medicinal chemistry, Mar, Volume: 44, Issue:3
Synthesis of modified pyrimidine bases and positive impact of chemically reactive substituents on their in vitro antiproliferative activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (55)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (10.91)18.7374
1990's6 (10.91)18.2507
2000's20 (36.36)29.6817
2010's18 (32.73)24.3611
2020's5 (9.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.02

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.02 (24.57)
Research Supply Index4.06 (2.92)
Research Growth Index4.90 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.02)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other57 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]